

9th August, 2023

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.
Ref.: Scrip Code No. : 540701 (Equity) : 974556 (Debt)	Ref. : (i) Symbol – DCAL (ii) Series – EQ

SUB.: DISCLOSURE PURSUANT TO REGULATION 30 OF SEBI (LODR) REGULATIONS, 2015: UPDATES ON EDQM AND JAPANESE PMDA AUDIT

Dear Sir,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, we hereby inform about the updates on EDQM and Japanese PMDA Audit as under:

➤ **EDQM Update at Bavla Site:**

As informed earlier, there was a joint inspection carried out during the quarter ending March, 2020 by the Swissmedic and European Directorate for the Quality of Medicines & HealthCare (EDQM), due to which there were certain audit observations issued deficient to EU GMP Part II and other relevant Annexes for the Company's Bavla site. There was an impact on the production at the Company's Bavla manufacturing site due to the observations received, which impacted the revenue and profitability of the Company's operations at Bavla since March 2020 till now.



The Company has been steadily ramping up manufacturing activities at the Bavla site in order to meet the customer requirements including successfully passing certain key customer audits at the Company's Bavla site. Further, pursuant to implementation of the Corrective Action Plan submitted to the EDQM on 21st August, 2020, the Company has informed the EDQM on 18th October, 2022 regarding its readiness for a re-inspection of its Bavla site with an objective of getting a clearance for this site by the EDQM.

The re-inspection by the EDQM of the Bavla site is scheduled from 18th September, 2023 to 20th September, 2023.

➤ **COMPANY'S BAVLA UNIT SUCCESSFULLY INSPECTED BY JAPANESE PMDA**

We would like to further inform that Company's Bavla site was successfully inspected by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) from 31st July, 2023 to 3rd August, 2023 though the final report is awaited.

Kindly take this on your record & oblige.

Yours faithfully,
For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary